skip to main content

Ovarian Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersOvarian CancerSCE Medical Oncology

A patient has platinum-resistant high-grade serous ovarian cancer after two previous systemic regimens. Validated testing shows folate-receptor-alpha expression above the required threshold. Which newly recommended NHS targeted treatment matches NICE TA1169?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Mirvetuximab soravtansine

NICE TA1169 recommends mirvetuximab soravtansine for FR-alpha-positive platinum-resistant high-grade serous ovarian, fallopian-tube or primary peritoneal cancer after one to three systemic regimens. The alternatives do not match the appraisal biomarker, tumour type and treatment-line criteria.

Reference: NICE TA1169: mirvetuximab soravtansine. https://www.nice.org.uk/guidance/ta1169/chapter/1-Recommendations